Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomized, Double-Blind Intervention Trial for Evaluating the Safety and Efficacy of Imatinib in Subjects With Advance Fibrosis

NCT05224128 is registered in ClinicalTrials.gov with Research Institute for Gastroenterology and Liver Diseases (RIGLD) as lead sponsor.

NCT NCT05224128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05224128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomized, Double-Blind Intervention Trial for Evaluating the Safety and Efficacy of Imatinib in Subjects With Advance Fibrosis
Lead sponsor
Research Institute for Gastroenterology and Liver Diseases (RIGLD)
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 20, 2021
Completion date
September 2, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis